CCL4 and Insulin resistance: While both TNF-α and IL-6 could be reduced by CCL4 inhibition, it will be interesting to elucidate whether a broader inhibition of systemic inflammation with a specific chemokine, such as CCL4, could improve insulin resistance in clinical diabetes.